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Background: Antibiotic resistance has become a serious global problem and is steadily increasing worldwide in
almost every bacterial species treated with antibiotics. In aquaculture, the therapeutic options for the treatment of
A. hydrophila infection were only limited to several antibiotics, which contributed for the fast-speed emergence of
drug tolerance. Accordingly, the aim of this study was to establish a medication regimen to prevent drug resistant
bacteria. To determine a rational therapeutic guideline, integrated pharmacodynamics and pharmacokinetics
parameters were based to predict dose and dosage interval of enrofloxacin in grass carp Ctenopharyngodon idella
infected by a field-isolated A. hydrophila strain.
Results: The pathogenic A. hydrophila strain (AH10) in grass carp was identified and found to be sensitive to
enrofloxacin. The mutant selection window (MSW) of enrofloxacin on isolate AH10 was determined to be 0.5 - 3
μg/mL based on the mutant prevention concentration (MPC) and minimum inhibitory concentration (MIC) value.
By using high-performance liquid chromatography (HPLC) system, the Pharmacokinetic (PK) parameters of
enrofloxacin and its metabolite ciprofloxacin in grass carp were monitored after a single oral gavage of 10, 20, 30
μg enrofloxacin per g body weight. Dosing of 30 μg/g resulted in serum maximum concentration (Cmax) of 7.151
μg/mL, and concentration in serum was above MPC till 24 h post the single dose. Once-daily dosing of 30 μg/g
was determined to be the rational choice for controlling AH10 infection and preventing mutant selection in grass
carp. Data of mean residue time (MRT) and body clearance (CLz) indicated that both enrofloxacin and its
metabolite ciprofloxacin present similar eliminating rate and pattern in serum, muscle and liver. A withdraw time of
more than 32 d was suggested based on the drug eliminating rate and pharmacokinetic model described by a
polyexponential equation.
Conclusions: Based on integrated PK/PD parameters (AUC/MIC, Cmax/MIC, and T>MPC), the results of this study
established a principle, for the first time, on drawing accurate dosing guideline for pharmacotherapy against A.
hydrophila strain (AH10) for prevention of drug-resistant mutants. Our approach in combining PK data with PD
parameters (including MPC and MSW) was the new effort in aquaculture to face the challenge of drug resistance
by drawing a specific dosage guideline of antibiotics.
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Fluoroquinolones such as enrofloxacin and ciprofloxacin
are widely used in the treatment of animal disease
caused by both Gram-negative and Gram-positive
bacteria [1]. The bactericidal activity of fluoroquinolones
is concentration-dependent, thus the peak level (Cmax)
and the amount of drug, as reflected by the area under the
concentration-versus-time curve (AUC) in serum, are
important predictors of the efficacy of fluoroquinolones
[2]. Enrofloxacin, a fluoroquinolone carboxylic derivative,
is Food and Drug Administration (FDA)-approved for
treatment of individual pets and domestic animals in the
United States. Enrofloxacin can be de-ethylated
in vivo to its metabolite ciprofloxacin with a rate that is
species-specific [3]. Aeromonas hydrophila (A. hydrophila)
is a ubiquitous Gram-negative bacterium causing fatal
hemorrhagic septicemia and dropsy in many commercially
important freshwater fish worldwide [4].
A. hydrophila is also considered one of the major
pathogens threatening the freshwater fish cultivation
industry including grass carp ctenopharyngodon idella,
the top aquaculture species of China [5]. Despite the
severe economic loss, no vaccination against A. hydrophila
infection has been commercially applied in China [6]. The
main reason for the lack of commercial vaccines might be
the existence of antigenic heterogeneity of various A.
hydrophila strains in the field. Until now, antibacterial
drugs through oral delivery are the popular and effective
choice for the control of pandemics causing by A.
hydrophila. In China, enrofloxacin is one of the effective
antimicrobials in grass carp farms and has been widely
applied in fish ponds nationwide for over 10 years [7].
Antibiotic resistance has become a serious global
problem and is steadily increasing worldwide in almost
every bacterial species treated with antibiotics [8]. In
aquaculture, the therapeutic options for the treatment of A.
hydrophila infection were only limited to several antibiotics,
which contributed for the fast-speed emergence of drug
tolerance [9]. Traditional one-for-all dosing guideline of
enrofloxacin is not applicable any more. The failure to
control bacterial disease in fish with antibiotics was most
likely to result from sub-optimal therapy, irrespective of the
degree of resistance. Enrofloxacin oral formulations have
been commercialized in China. Farmers can use it to
feed fish to treat bacterial infection. In fact, more and
more pandemic A. hydrophila strains isolated from
the diseased fish were with reduced susceptibility to
enrofloxacin [10]. Given this, there is an urgent need
to develop a medication regimen that prevents the
formation of drug resistant bacteria.
Recently, new approaches were tested with an aim
to increase efficacy of antibacterial drugs and to
reduce resistance selection. It is well established that
serum Cmax/MIC (ratio of maximum drug concentrationto minimum inhibitory concentration) >8 and AUC/MIC
(ratio of area under the concentration-time curve to
minimum inhibitory concentration) >100 are required for
efficient and optimal pharmacotherapy of enrofloxacin
[11]. The mutant prevention concentration (MPC) is a new
concept meant to face the increased prevalence of antibiotic
resistance by using antibiotic concentrations able to prevent
the selection of resistant bacteria populations [12]. Since
T>MPC, exposure time of drug concentration above MPC,
served as a more important factor in preventing drug resist-
ance, AUC/MIC, Cmax/MIC and T>MPC were important
integrated PK/PD parameters.
The aim of the present study was to develop a medication
regimen against a disease caused by A. hydrophila strain
(AH10) in grass carp by integrating pharmacodynamic
(including MPC and MSW) and pharmacokinetic parame-
ters for enrofloxacin. Although enrofloxacin is widely used
as antimicrobial agent, its PK or PD parameters in grass
carp are lacking. 10 ~ 30 μg/g is the dose of recommended
in the industry [13]. To clarify the PK indices, oral dosing of
10, 20, and 30 μg/g body weight were individually examined
in the study. The results of this study paved the way for
establishing dosing guidelines to avoid selecting resistant
mutants of specific fish bacterial pathogen with uncertain
drug-susceptibility.
Results and discussion
The median lethal dose (LD50) of A. hydrophila (AH10) on
grass carp
A. hydrophila was the most destructive bacterial patho-
gen of farmed grass carp. AH10 strain was isolated and
identified according to the method of Roxana et al. [14]
from diseased grass carp in 2011 (NCBI accession number:
JX413114.1). The pathogen was stored in National Aquatic
Pathogen Collection Center (No. 2011AH10). Grass carp
was susceptible to laboratory infection with isolate
AH10. External clinical signs of the infection included
haemorrhaging and erratic swimming behavior. The
seven day LD50 for grass carp by intraperitoneal route
was 1.18 × 106 CFU/mL (the 95% confidence interval
was 5.53 × 105 ~ 2.42 × 106 CFU/mL), which was analyzed
from the data in Table 1 by SPSS 16.0 software. Based on
the clinical symptom and values of LD50, isolate AH10
should be regarded as a virulent strain.
Activities of enrofloxacin on A. hydrophila (AH10) in vitro
The in vitro activities of enrofloxacin on isolate AH10 were
subsequently investigated. The MIC value of enrofloxacin
on isolate AH10 was 0.5 μg/mL, and that of quality control
strain A. hydrophila ATCC 7966 was 0.25 μg/mL. The
isolate AH10 was less sensitive to enrofloxacin than control
strain ATCC7966. MPC values should be considered in
drawing dosing strategies since traditional MIC-based
dosing level might give rise to treatment failure due
Figure 1 Replication of isolate AH10 after 1 h exposure to
enrofloxacin at indicated concentration. Control groups (C1 and
C2) referred to bacterial without drug treatment. (n = 3,The mean ± SD).
After 1 h exposure to enrofloxacin with a concentration as indicated in
the figure, the concentration of isolate AH10 was determined to be
8.71 × 103 CFU/mL (C1), 8.51 × 103 CFU/mL (C2), 8.71 × 102 CFU/mL
(2 MIC), 5.50 × 102 CFU/mL (4 MIC) and 3.63 × 102 CFU/mL
(8MIC), respectively.







Dead number of fish Accumulated
dead number1d 2d 3d 4d 5d 6d 7d
2.5 × 103 10 0 0 0 0 0 0 0 0
2.5 × 104 10 0 0 1 1 0 0 0 2
2.5 × 105 10 1 2 1 1 0 0 0 5
2.5 × 106 10 2 3 1 2 0 0 0 8
2.5 × 107 10 5 3 2 10
2.5 × 108 10 10 10
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of enrofloxacin on isolate AH10 was determined to
be 6 MIC (3 μg/mL), which was above the resistance
breakpoint for enrofloxacin (≥ 2 μg/mL). The MSW
of enrofloxacin on isolate AH10 was determined to
be 0.5 – 3.0 μg/mL, which reflected the difference
between the measured MIC and MPC values. Existence of
the MSW allowed us to predict the likelihood for resistance
selection or prevention based on achievable and therapeutic
drug concentrations [15]. Selective amplification of the
non-susceptible AH10 population was expected to occur in
the identified MSW of enrofloxacin. As far as we knew, this
was the first study trying to apply MPC principles to
optimize therapy and reduce resistance selection of fish
bacterial pathogen.
The post antibiotic effect (PAE) may contribute to the
in vivo efficacy of enrofloxacin [16]. It was well known
that enrofloxacin prevented the synthesis of bacterial
DNA by gyrase, the PAE might represent the time for it
to dissociate from the receptor binding sites and to
diffuse out of the bacterium. It was generally believed
that PAE was concentration dependent and directly
related to the exposure time [17]. In this study, PAE of
enrofloxacin was evaluated by exposure of isolate AH10
to it at 2, 4, and 8 times MIC for 1 h (Figure. 1). The PAE
of enrofloxacin was 1.44 ± 0.36h, 1.57 ± 0.09h, 1.83 ± 0.21h,
respectively. The data predicted that the dosing interval
deduced from the time-concentration PK curve could
be 1 – 2 h longer due to the existence of PAE. Although
the in vivo PAE of enrofloxacin was still awaiting further
investigation, our data at least suggested that the T>MPC
seemed to be the dominant factor in drawing dose intervals
since PAE of enrofloxacin was comparably short.
Pharmacokinetics of enrofloxacin in grass carp
HPLC presents a simple, rapid, and reliable analytical
method for detection and quantification of enrofloxacin
and its metabolite ciprofloxacin. In our HPLC system, the
limit of detection (LOD) for enrofloxacin and ciprofloxacin
was 0.02 μg/mL and 0.004 μg/mL, respectively. The sample
concentration was calculated by comparison of itspeak area with the peak area of a nominal concentration of
an external standard. The chromatography area and
the concentration of enrofloxacin and ciprofloxacin
showed a linear relationship. The standard curve equation
of enrofloxacin is y = 191.7× - 52.68 (r = 0.9995), and the
standard curve equation of ciprofloxacin is y = 92.74× –
12.00 (r = 0.9999). The standard was routinely corrected by
the concentration factor and the recovery rate [18]. The
linearity of our method was confirmed using the classical
tests by analysis of variance.
The concentration-time profiles of serum and tissue
after an oral dose of 10 μg/g, 20 μg/g, and 30 μg/g
were separately shown in Figure 2. In general, high
dose (20 μg/g and 30 μg/g) resulted in a shorter time
(0.5 h) to peak level than lower dose (1 h for dose of
10 μg/g), and the time to reach the peak level in
muscle (≥10 h) was much longer than serum & other
tissues for all the three doses. 24 h post drug delivery,
serum concentration of enrofloxacin was 0.801 μg/mL,
1.918 μg/mL, and 2.953 μg/mL, respectively. The low
elimination rate generally predicted a positive clinical
result and correlated with the extensive application of
enrofloxacin in controlling bacterial disease in grass carp.
Peak levels (Cmax) of liver (8.941 μg/g, 18.344 μg/g, and
20.076 μg/g, respectively) was the highest, followed by
kidney (3.362 μg/g, 8.152 μg/g, and 9.587 μg/g),
serum (2.837 μg/g, 5.685 μg/g, and 7.150 μg/g), and
muscle (1.320 μg/g, 2.369 μg/g, and 2.628 μg/g). These
data were basically in consistence with PK parameters of
enrofloxacin in other fish species [19].
All the data were analysed by Kinetica4.4, the results
showed that it was a two-compartment model with zero
absorption in serum, liver and kidney, a two-compartment
model with first-order absorption in muscle (Table 2). The
Figure 2 Enrofloxacin concentration-time curves in serum and tissues of grass carp at different administration doses. Standard deviation is given
at vertical bars (n = 5, The mean ± SD). At three doses of enrofloxacin, the Cmax of enrofloxacin in liver is highest and the Cmax of enrofloxacin in muscle is
lowest. The time to Cmax in muscle for enrofloxacin was significantly longer than in serum and other tissues. (A: Serum; B: Liver; C: Muscle D: Kidney).
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criteria (>5) were obtained. Listed PK parameters
were demonstrated in Table 3. It was worth to note
that model-independent parameters such as elimination
half-life (t1/2), area under the curve (AUC), and clearanceTable 2 Best concentration-time equations of
enrofloxacin in grass carp
Dose Tissues Equation
10 μg/g
Serum C = 0.844e-0.114t + 0.500e-0.016t
Liver C = 3.007e-0.087t + 1.634e-0.005t
Muscel C = 3.334e-0.022t + 1.025e-0.159t – 4.359e-0.2656t
Kidney C = 1.109e-0.027t + 0.164e-0.025t
20 μg/g
Serum C = 1.707e-0.166t + 1.600e-0.015t
Liver C = 9.072e-0.191t + 4.631e-0.015t
Muscel C = 4.630e-0.055t + 0.758e-0.003t – 5.388e-0.216t
Kidney C = 7.39859e-0.0244547t + 4.01081e-0.0626125t
30 μg/g
Serum C = 3.904e-0.164t + 3.013e-0.007t
Liver C = 14.577e-0.066t + 5.887e-0.004t
Muscel C = 2.269e-0.066t + 1.365e-0.005t – 3.634e-0.211t
Kidney C = 6.154e-0.044t + 4.044e-0.036t(CLs) were calculated for each of the five fish and averaged
in the table.
The serum concentration was the key factor for drug
effectivity. At the tested oral dose of 10 μg/g, 20 μg/g and
30 μg/g in three independent experiments, the distribu-
tion half life (T1/2α) of enrofloxacin in serum was 6.098 h,
4.186 h, and 4.348 h, respectively. AUC of enrofloxacin
in serum was 72.538 μg/mL·h, 171.984 μg/mL·h, and
318.187 μg/mL·h, respectively. These data suggested
that higher dose resulted in significant higher AUC
value or clinical result than lower dose, but with a
similar absorption rate. The muscle concentration
might be important in deciding the withdrawal time.
The terminal (elimination) half life (T1/2β) of enrofloxacin
in muscle was 95.070 h, 150.884 h, and 161.381 h,
respectively. The AUC value of enrofloxacin in muscle was
129.154 μg/mL·h, 175.160 μg/mL·h, and 188.914 μg/mL·h,
respectively. These results implied that the elimination rate
in muscle was low and seemed independent of the dose
level at higher dose (20 μg/g and 30 μg/g), and the similar
AUC value of the two dosal levels further suggested that
the withdrawal time might be similar, which was ideal for
disease and drug-residual control since better clinical result
might be achieved by increasing the dose level while keep-
ing a similar withdrawal time.




10 mg/kg 20 mg/kg 30 mg/kg
Serum Liver Muscle Kidney Serum Liver Muscle Kidney Serum Liver Muscle Kidney
A(μg/mL) 0.844 3.007 3.334 1.109 1.707 9.072 4.630 7.162 3.904 14.577 2.269 6.154
B(μg/mL) 0.500 1.634 1.025 0.164 1.6 4.631 0.758 3.682 3.013 5.887 1.365 4.044
Α(/h) 0.114 0.087 0.022 0.027 0.166 0.191 0.055 0.024 0.164 0.068 0.066 0.044
Β(/h) 0.016 0.005 0.159 0.025 0.015 0.015 0.003 0.063 0.007 0.004 0.005 0.036
Ka(/h) 0.491 0.275 0.266 0.478 0.671 1.787 0.216 0.764 0.502 1.445 0.211 0.676
Kel(/h) 0.037 0.020 0.013 0.027 0.024 0.019 0.160 0.024 0.015 0.013 0.143 0.024
T1/2α(h) 6.098 0.080 3.126 25.938 4.186 36.262 12.595 28.344 4.348 10.145 10.515 27.775
T1/2β(h) 42.728 86.253 95.070 42.375 46.757 110.452 150.884 107.861 97.363 184.996 161.381 124.271
Tmax(h) 1.000 1.000 48.000 1.000 0.500 0.500 16.000 0.500 0.500 0.500 10.000 0.500
MRT0-t(h) 44.566 62.765 63.938 55.871 51.841 63.093 67.096 56.620 144.573 65.005 68.159 56.620
Cmax (μg/mL) 2.837 8.941 1.320 3.362 5.685 18.344 2.369 8.152 7.151 20.076 2.628 9.587
AUC24 (μg/mL·h) 25.838 66.108 21.683 33.183 67.585 114.168 40.349 49.589 90.486 242.313 44.666 66.359
AUC (μg/mL·h) 72.538 210.118 129.154 102.899 171.984 338.316 175.160 127.511 318.187 425.763 188.914 181.293
CLs (L/kg·h) 0.155 0.030 0.054 0.080 0.100 0.029 0.095 0.108 0.067 0.020 0.124 0.122
A(μg/mL), Intercept of the linear equation on log transformed data; B(μg/mL), Slope of the linear equation on log transformed data; α(/h), Distribution rate
constant; β(/h), Elimination rate constant; Ka(/h), Absorption rate constant; Kel(/h), elimination rate constant from the central compartment; T1/2α(h), Half-life of
distribution; T1/2β(h), Half-life of elimination; Tmax(h), Time required to reach Cmax in the interval; MRT0-t(h), Mean residue time of drug in body from zero to 168h;
Cmax(μg/mL), Maximum concentration in the interval; AUC24(μg/mL·h), Area under the drug concentration-time curve from the time zero to 24h; AUC(μg/mL·h),
Area under the drug concentration-time curve from the time zero to last time point; CLs(L/kg·h), total body clearance.
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grass carp
Although this study was aimed to examining potential
dosage regimens for enrofloxacin against a specific bacterial
pathogen, the PK parameters of its major metabolite
ciprofloxacin was investigated in parallel with the
analysis of enrofloxacin. It was well accepted that the
rate of transformation of enrofloxacin to ciprofloxacin
in aquatic animals was significantly less than that in
terrestrial animals [3], which suggested that enrofloxacin
was mainly responsible for clinical efficacy in fish. How-
ever, the marker residue for tissues after oral dose of
enrofloxacin was the sum of the enrofloxacin and ciproflox-
acin residues. Although ciprofloxacin itself was forbidden to
be used in aquatic species, the permitted residue level of
ciprofloxacin in fish was 0.030-0.050 μg/g in most countries.
Thus, PK parameters of ciprofloxacin would be helpful in
determining a suitable withdrawal time for enrofloxacin in
grass carp.
Figure 3 depicted the time course of metabolite
ciprofloxacin concentrations in serum, liver, kidney, and
muscle from grass carp after oral gavage of enrofloxacin at
a dose of 10 μg/g, 20 μg/g, and 30 μg/g, respectively. In
general, ciprofloxacin was detectable 0.5 h after drug
delivery and high dose resulted a shorter time to reach
Cmax. As expected, only a small portion of enrofloxacin
was transmitted to ciprofloxacin. At the dose of 30 μg/g ofenrofloxacin, the Cmax of ciprofloxacin in serum,
liver, muscle, and kidney was only 0.254 μg/mL,
1.480 μg/g, 0.329 μg/g, and 0.386 μg/g, respectively.
Similar to enrofloxacin, the time to Cmax in muscle
for ciprofloxacin was significantly longer than in
serum and other tissues. For example, the Tmax for
serum, liver, kidney, and muscle at the dose of 30 μg/g
was 0.5 h, 0.5 h, 1 h and 4 h, respectively.
Analyzed by Kinetica4.4, the concentration-time profiles
of ciprofloxacin could be described by a one-compartment
model (Table 4). The correlation coefficient exceeded 0.99
and high model criteria (>5) were obtained.
Listed PK parameters were demonstrated in Table 5. By
comparison of the AUC of enrofloxacin and ciprofloxacin
at different dosage (10 μg/g, 20 μg/g, 30 μg/g), the
transformation rate of enrofloxacin to ciprofloxacin in
serum was determined to be 0.85%, 1.13% and 1.87%,
respectively. In liver, the rate was 4.93%, 6.09% and
7.59%, respectively; in kidney, the rate was 1.29%, 1.74%,
and 1.88%, respectively; in muscle, the rate was 1.10%,
1.38%, and 2.33%, respectively. Although ciprofloxacin dem-
onstrated a similar residue time (MRT0-t) than enrofloxacin,
the CLs of ciprofloxacin was higher than enrofloxacin at all
the three doses, which suggested that the withdrawal
time could be decided according to the time to reach
zero residue level of enrofloxacin since the elimination
rate of ciprofloxacin was faster.
Figure 3 Ciprofloxacin concentration-time curves in serum and tissues of grass carp at different administration doses of enrofloxacin.
Standard deviation is given at vertical bars. (n = 5, The mean ± SD). At three doses of enrofloxacin, the Cmax of ciprofloxacin in liver is highest and
the Cmax of ciprofloxacin in serum is lowest. Similar to enrofloxacin, the time to Cmax in muscle for ciprofloxacin was significantly longer than in
serum and other tissues. (A: Serum; B: Liver; C: Muscle D: Kidney).
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PK/PD parameters
Overuse and misuse of antimicrobial drugs had favoured
the growth of resistant organisms. Inappropriate dosage
regments included misuses in dose, dosage interval,
duration of treatment, route and conditions of administra-
tion. In this study, we focused on dose and dosage interval
selection. Traditional PK/PD indices (AUC/MIC, T >MIC,
and Cmax/MIC) have been proposed to predict the success
or failure of therapy, which only considered one PD
biomarker, MIC. Although positive clinical outcome might
be achieved by a dosage regimen based on these indices, it
didn’t rule out the possibility of selecting drug-resistant
mutant. Challenged by the emergence and spread of various
resistance strains worldwide, the concepts of MSW and
MPC provided new conceptual basis for PK/PD approaches
in deciding dosing guidelines: treatments should maximize
the time during which enrofloxacin cocentrations at the site
of infection were above the MPC, and minimize the time
during which these concentrations were in the MSW.
Thus T>PC, instead of of T>MIC, was considered the
most important factor in deciding dose regimens for
the prevention of mutant selection. Although tissue drug
concentration demonstrated difference with serum, serumconcentration was more relevant in predicting antibiotic
efficacy. Thus, serum PK/PD parameters were the major
data that was based to draw a dosing guideline here
(Table 6 and Figure 4).
In general, AUC24/MIC > 100 and Cmax/MIC > 8 predicted
a clinical outcome of enrofloxacin [11]. In our analysis,
AUC24/MIC and Cmax/MIC of enrofloxacin in serum
were 51.68 and 5.68 at the dosage of 10 μg/g,
respectively; 135.17 and 11.37 at the dosage of 20 μg/g, re-
spectively; 180.97 and 14.30 at the dosage of 30 μg/g,
respectively (Table 6). The data suggested that a dosage
more than 20 μg/g might achieve good enough therapeutic
result. However, the T>MPC for the 20 μg/g dosage was
only 10 h, while T>MPC for the 30 μg/g dosage could reach
24 h. To prevent selection of resistant mutant, the dosage
interval for the level of 20 μg/g was 10 h, which
suggested a twice-daily dose. In contrast to it, once-daily
dose of 30 μg/g was adequate for the maximum time of
enrofloxacin concentration above MPC. Apparently,
dosage level of 30 μg/g was more cost-effective. PAE
of enrofloxacin at both these two dosages were 1–2
h in our assay, thus PAE wouldn’t significantly affect
the choice of dosage interval for enrofloxacin in
grass carp.
Table 4 Best concentration-time equations of
ciprofloxacin in grass carp
Dose Tissues Equation
10 μg/g
Serum C = 0.119e-0.010t + 0.119e-0.078t
Liver C = 0.178e-0.008t + 0.178e-0.249t
Muscel C = 0.048e-0.001t + 0.048e-0.171t
Kidney C = 0.125e-0.011t + 0.125e-0.202t
20 μg/g
Serum C = 0.175e-0.009t + 0.175e-0.268t
Liver C = 0.451e-0.008t + 0.451e-0.222t
Muscel C = 0.188e-0.003t + 0.188e-0.171t
Kidney C = 0.222e-0.012t + 0.222e-0.214t
30 μg/g
Serum C =0.209e-0.007t + 0.209e-0.248t
Liver C = 0.710e-0.007t + 0.710e-0.217t
Muscel C = 0.260e-0.005t + 0.260e-0.222t
Kidney C = 0.488e-0.015t + 0.488e-0.211t
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istering enrofloxacin at 10 mg/kg in medicated water
to turkeys was evaluated by applying a PK/PD approach
to the kinetic parameters obtained after oral pulsed
administration and to the MIC values of avian pathogenic
Escherichia coli (APEC) strains isolated from commercial
turkey flocks. The results were different from ours because
of different tested animal species and pathogens, more
importantly due to the different MIC values. Study on
PK-PD indices of enrofloxacin in Escherichia coli
O78/H12 infected chickens [21] also showed that PK-PD
studies should include not only AUC/MIC and Cmax/MIC
estimation but also determination of MPC values, which
could describe better response of bacterial strain to theTable 5 PK parameters of ciprofloxacin in grass carp (n = 5)
Tissues
Parameter 10 mg/kg
Serum Liver Muscle Kidney Serum L
A(μg/mL) 0.104 0.172 0.048 0.118 0.169 0
Α(/h) 0.01 0.008 0.001 0.011 0.009 0
Ka(/h) 0.078 0.249 0.171 0.202 0.268 0
Kel(/h) 0.031 0.027 0.016 0.019 0.02 0
T1/2α(h) 70.300 54.558 126.553 46.273 74.727 74
Tmax(h) 6.000 1.000 48.000 6.000 1.000 0
Cmax(μg/mL) 0.187 0.759 0.233 0.188 0.225 1
MRT0-t(h) 61.453 61.61 60.652 59.982 64.912 62
AUC(μg/mL·h) 8.392 17.09 2.704 7.633 13.516 29
CLs(L/kg·h) 0.920 0.429 17.893 0.913 1.078 0
A(μg/mL), Intercept of the linear equation on log transformed data; α(/h), Distributi
constant from the central compartment; T1/2α(h), Half-life of distribution; Tmax(h), T
concentration in the interval; MRT0-t(h), Mean residue time of drug in body from ze
the time zero to last time point; CLs(L/kg·h), total body clearance.used fluoroquinolones. The high dose (2.5 ml enrofloxacin/
1 L drinking water) of enrofloxacin was better than low
dose (0.5 ml enrofloxacin solution/1 L drinking water) for
efficient eradication of bacteria.
Reasonable dosage regimen should be based on PK/PD
studies and determined by practical application of the test
animals. The size of the dose and dosing interval were the
key indices to meet the requirement of positive clinical
outcome of fish: enough time of in vivo therapeutic
concentrations, no adverse effects on the body, and
acceptable withdrawal period. Usually concentration-
dependent antibacterial drugs, like enrofloxacin, should be
delivered through once-daily dosing approach, which was
crucial for higher Cmax or Cmax/MIC ratio to maximize the
opportunity to get the best bactericidal action and clinical
effect. The fact that Gram-negative bacteria became
temporarily and reversibly adaptive resistant 2 h after
administration of antimicrobial drugs also suggested
that longer dosing interval could reduce the risk for
development of adaptive resistance by microorganisms
[22]. Thus, Once-daily drug delivery also contributed
to maximize the bacterialcidal effect of enrofloxacin
by avoiding adaptive resistance.
Recommended withdrawal time based on the elimination
rate of enrofloxacin and ciprofloxacin
Many countries protected consumer health from possible
drug residues in fish by setting tolerable concentrations of
drug residues, and surveillance agencies had been checking
for compliance with the relevant directives. To ensure
delivery of safe fish products to consumers, the withdrawal
time of drugs must be respected [23]. It was worth to
mention that the elimination rate of both enrofloxacin andDose
20 mg/kg 30 mg/kg
iver Muscle Kidney Serum Liver Muscle Kidney
.435 0.185 0.21 0.203 0.687 0.254 0.453
.008 0.003 0.012 0.007 0.007 0.005 0.015
.222 0.171 0.214 0.248 0.217 0.222 0.211
.028 0.012 0.022 0.019 0.025 0.012 0.023
.283 129.297 57.892 92.733 98.544 140.684 63.202
.500 10.000 2.000 0.500 0.500 4.000 1.000
.219 0.276 0.348 0.254 1.480 0.329 0.386
.200 71.581 63.192 69.093 67.674 73.703 64.946
.941 21.380 12.166 17.665 55.732 26.675 18.329
.214 0.272 0.572 1.072 0.102 0.210 0.331
on rate constant; Ka(/h), Absorption rate constant; Kel(/h), elimination rate
ime required to reach Cmax in the interval; Cmax(μg/mL), Maximum
ro to 168h; AUC(μg/mL·h), Area under the drug concentration-time curve from
Table 6 Serum PK-PD parameters
Dosage(μg/g) Cmax/MIC AUC24/MIC MPC(ug/ml) MSW(ug/ml)
10 5.68 51.68 3.0 0.5 ~ 3.0
20 11.37 135.17 3.0 0.5 ~ 3.0
30 14.30 180.97 3.0 0.5 ~ 3.0
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due levels apparently represented the length of withdrawal
period. From the concentration-time equations of both
enrofloxacin and ciprofloxacin at a dosage of 30 μg/g in
muscle (Table 2 and 4), it would take at least 32 d for
enrofloxacin (32 d) and ciprofloxacin (15 d) to be depleted
to a permitted residue level of 30 μg/kg. According to the
present data, the proposed withdrawal period in grass
carp should not be less than 32 d. Both enrofloxacin
and ciprofloxacin levels reached to the detection limit
of our HPLC system at 32 d after the dosage of 30 μg/g,
and became undetectable at 37 d post drug delivery. This
result partially validated our PK/PD parameters. However,
the present study didn’t consider the effect of continuous
drug delivery (generally 3–7 d for bacterial disease)
on the elimination rate of enrofloxacin or ciprofloxacin, a
withdrawal period of more than 32 d might be expected.
Conclusions
The PD parameters (MIC, MPC, and MSW) of A. hydrophila
AH10, isolated from grass carp Ctenopharyngodon
idella, were characterized. The PK parameters in
serum and tissues (liver, kidney, and muscle) of
enrofloxacin following a single oral treatment in grass
carp Ctenopharyngodon idella at three different dosage
levels (10, 20, and 30 μg/g) were investigated. Integrated
PK/PD parameters (AUC/MIC, Cmax/MIC, and T>MPC)
suggested that once-daily dosage of 30 μg/g predicted a
positive clinical outcome and minimize the selection of
drug-resistant AH10 mutant. Our approach in combiningFigure 4 Dtermination of T>MPC at the indicated dosing levels
(n = 5, The mean±SD). The T>MPC for the 10 μg/g dosage was 0 h,
the T>MPC for the 20 μg/g dosage was 10 h, while T>MPC for the
30 μg/g dosage could reach 24 h.PK data with PD parameters (including MPC and MSW)
was the new effort in aquaculture to face the challenge
of drug resistance by drawing a specific dosage guideline
of antibiotics.Methods
Fish
All animal procedures were reviewed and approved
by the Institutional Animal Care and Use Committee
at Shanghai Ocean University. Animal care and
experimentation were undertaken in accordance with
Ocean University of Shanghai animal care guidelines.
500 grass carp Ctenopharyngodon idellas (body
weight of around 200 g) were obtained from a fish
hatchery in Shanghai, China and maintained in 600-L
fiberglass tanks with circulating, filtered and well-aerated
tap water at 22.0 ± 1.0°C under a 12:12 h day:night cycle
and were reared under normoxia (7.0 ± 0.2 mg O2/L) for
2 week prior to experimentation, and with no history
of fluoroquinolone treatment. The fish were being fed
daily with artificial feed (Charoen Pokphand Group).Chemicals
Enrofloxacin and ciprofloxacin powder standards were
obtained from Sigma (St Louis, MO, USA). Prototype
enrofloxacin (≥99%) was supplied from Zhejiang Xinchang
Pharmaceutical Co., Ltd. Organic solvents used in this
study were of HPLC grade (Sigma-Aldrich, China). other
chemicals were analytical grade (Dingguo Biotech, Beijing);
Mueller-Hinton Broth (MHB) and Mueller-Hinton Agar
(MHA) was supplied from Sinopharm Chemical Reagent
Beijing Co., Ltd.Drug administration
In oral gavages, the fish were divided into three groups
(300, 100/group), fish were given a dose of 10, 20, 30 μg/g
body weight individually. Enrofloxacin solution (60 g/L)
was forced into the stomach of the grass carp using a 1-ml
syringe fitted with an obtuse 7# gauge needle. (225 fish
were killed after the end of the experiment.)Sample collection
Five live fish were sampled at intervals ranging from
0.5-168 h after the administration. Fish were anesthetized
with 2-phenoxyethanol (2 mL/L) before handling. One
milliliter of blood was drawn into heparinized syrin-
ges from the caudal artery. Blood samples were
centrifuged at 10000 × g for 10 min, the serum was
then collected and stored at −20°C. Fish were than
euthanized by concussion. Liver, kidney, and muscle
tissues were taken and frozen at −20°C.
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HPLC (high performance liquid chromatography)
Serum and tissue concentrations of enrofloxacin and
ciprofloxacin were assayed by HPLC. HPLC analysis
was performed with Agilent 1100 consisted of double
pump, auto-injector, column temperature tank, and
fluorescence detector that was set at 280 and 450 nm
as excitation and emission wavelengths, respectively.
The mobile phase consisted of acetonitrile and 0.01
M tetrabutylammonium bromide solution (5:95 V/V).
The pH of tetrabutylammonium bromide solution was
adjusted to 3.1 by phosphoric acid. Zorbax SB C-18
column (4.6 × 150 mm) was used for the separation. The
flow rate was 1.0 ml/min. The column temperature was
controlled at 40°C. External standards were enrofloxacin
and ciprofloxacin (Sigma-Aldrich, China).
Extraction of the compounds from serum and tissue
samples were achieved with 90% acidified acetonitrile
(containing 1% acetic acid) and 10% 0.15M hydrochloric
acid according to a modified protocol [3]. Recovery and
precision of the method, as well as the standard calibration
curves, were determined by a routine method [24]. For
both enrofloxacin and ciprofloxacin, the assay was linear
between 0.01 and 10 μg/ml or μg/mg.
LD50
In order to estimate the median lethal dose 50% (LD50)
of isolate AH10, duplicated groups of grass carp of
100–120 g (50, 10/group) were injected intraperitoneally
with 200 μl of serial dilutions of isolate AH10, from 1 × 103
to 1 × 108 CFU/ml. Control groups were injected with PBS.
Mortalities were recorded for 7 days. (35 fish were killed
after the end of the experiment.)
MIC
Minimum inhibitory concentration (MIC) was determined
by the double-tube method [25,26]. Briefly, 1 ml of
128 μg/mL enrofloxacin was dissolved in 1 ml fresh
Mueller-Hinton Broth (MHB) media in tube #1. Subse-
quently, 1 ml of culture from tube #1 was removed and
added to tube #2 containing 1 ml MHB media. The series
of dilutions was carried out for a total of 12 tubes. All
12 testing tubes along with 2 control tubes were
separately inoculated with 20 μL (106 CFU/mL)
isolate AH10 suspension and incubated in a 30°C
(the optimum growth temperature of A. hydrophila
strain is 28 ~ 30°C) incubator for 24 h. The lowest
drug concentration among tubes with no bacterial
growth would be the drug’s minimum inhibitory
concentration (MIC). This experiment was performed
in 3 replicates. Reference strain A. hydrophila strain
ATCC 7966 (store in Key Laboratory of Freshwater
Fishery Germplasm Resources, Shanghai) was used
for quality control.MPC and MSW
The mutant prevention concentration (MPC) indicated
the susceptibility of the small number of resistant mutant
bacterial present before any drug treatment. The MPC
was determined by methods described by Frederique
Pasguali et al. [27]. Briefly, isolate AH10 was cultured in
MHB media for 24 h. Then this cultured suspension was
centrifuged (at 4000 × g for 10 min) and used MHB
media to resuspend the isolate AH10 to a concentration of
1010 CFU/mL. 300 μL isolate AH10 suspension, containing
more than 1010 CFU/mL, were plated on each of four
Mueller-Hinton Agar (MHA) plates supplemented
with either enrofloxacin at concentration equal to 1×,
2×, 3×, 4×, 5×, 6×, 7×, 8×, 9×, 10× MIC. Plates were
incubated at 30°C for 48h, colonies counted and incubated
again for an additional 72h. The MPC was recorded as the
lowest drug concentration preventing the emergence of any
mutant after 48h and 120h incubation. Each experiment
was carried out three times.
PAE
Post antibiotic effect (PAE) was classically defined as the
period of bacterial growth suppression that persisted
after a limited exposure of organisms to antimicrobials.
In establishing dosing schedule, duration of PAE should
be added to the effective therapeutic period, which was
drawn from the time window with a concentration
more than MIC or MPC. The presence of PAE was
determined by methods described by Gudmundsson
[28]. To assess PAE, isolate AH10 (2.5 × 103 CFU/ml)
was exposed to enrofloxacin at 2 – 8 MIC for 1 h.
At the end of the exposure period, the antibiotic was
removed by diluting 1: 103 into the same prewarmed
medium. For quantification of the PAE, viable counts
were determined before and after drug exposure, and
then hourly for 12 h. PAE was expressed in hour and
determined by the formula PAE = T-C. T represented
the time for the drug-treated inoculum to amplify to
a concentration of 10 folds of the starting point, C
represented the time for the untreated control culture
to increase to 10 folds of its starting point.
Pharmacokinetic analysis
The computer program Kinetica4.4 (Thermo Fisher
Scientific) was used to derive pharmacokinetic values,
which described the drug concentration-time data
very well. The pharmacokinetic parameters were analyzed
based on statistical moment theory for the serum and
tissues concentration-time data of enrofloxacin and its
active metabolite ciprofloxacin. The following PK
parameters were determined and analyzed: Cmax (peak
concentration), T1/2α (half-life of the absorption rate
constant), T1/2β (half-life of the elimination rate constant),
AUC24 (area under the concentration-time curve from
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from zero to 168 h), and CLs (total body clearance).
Pharmacodynamics analysis
Due to the determined low transformation rate (less
than 5%) of enrofloxacin to ciprofloxacin in this
study, the antibiotic function of ciprofloxacin was
found insignificant as a metabolite. Pharmacodynamics
analysis was only performed on enrofloxacin. By integrating
experimental pharmacokinetic data and in vitro activities of
enrofloxacin on isolate AH10, optimal microbiological
outcomes were most likely predicted by Cmax/MIC,
AUC/MIC, and T>MPC.
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